SUMMARY Many patients with idiopathic Parkinson's disease treated with levodopa for more than five years develop fluctuations in their clinical response to this drug. Such fluctuations may be unpredictable, but more commonly occur in a regular pattern related to the size and timing of the levodopa dosage. Theories as to their cause have emphasised both the progression of the underlying Parkinson's disease and the possibility of a late side-effect of levodopa. We report two children with Parkinsonism, one after recurrent obstructive hydrocephalus and the other following an encephalitic illness. Both patients had striking improvement with levodopa, but developed predictable and unpredictable dramatic response fluctuations within weeks of starting levodopa therapy. This suggests that neither the pathology of idiopathic Parkinson's disease, nor the long-term use of levodopa are essential for the development of predictable or unpredictable fluctuations in response to levodopa therapy.
Sudden changes in disability are characteristic of untreated idiopathic Parkinson's disease, and a marked diurnal variation in symptoms is a common feature of juvenile paralysis agitans.' Such variation in disability, however, becomes much worse in many patients with Parkinson's disease on long-term levodopa therapy. About 50% or more of such patients treated with levodopa for five or more years develop response fluctuations. These swings usually are predictablie and related to timing of dosage ("early morning akinesia", "end-of-dose deterioration" or the "wearing-off' effect). Less common are sudden unpredictable swings from "on" to "ofW' lasting several minutes to hours. The causes of such predictable and unpredictable response variations are unknown, but these complications rarely occur during the first two years of treatment. One theory suggests that they are the consequence of levodopa therapy. Another hypothesis is that they are due to *Present address: Division of Neurology, Toronto Western Hospital, Toronto, Canada. progression of the underlying disease. It is of interest, therefore, to find that two children with symptomatic Parkinsonism developed typical end-ofdose deterioration as well as unpredictable response fluctuations within a few weeks of starting levodopa therapy. Examination then revealed head and eye deviation to the left, a severe Parkinsonian rest tremor of both arms, right more than left, and rigidity and dystonic posturing of all limbs in flexion. One month later he again became more drowsy, the tremor increased, and a CT scan showed recurrence of the hydrocephalus requiring a fifth shunt revision. After the last operation Sinemet was begun and the dose gradually increased to 110 mg twice daily in the first week. At this time, by when a further CT showed ventrides of normal size, his level of consciousness began to improve slowly. Over the following three weeks, as Sinemet dosage was increased further, motor function also improved. However, on Sinemet 110 mg four times daily, he then began to show fluctuations between Parkinsonian akinesia and periods of mobility with dyskinesias. During the "off" periods he was bed-bound with severe rigidity, akinesia, anarthria with drooling, a flexed posture and postural instability. During the "on" phase his tone was normal with no tremor, speech was more easily understood, the flexed posture was not apparent and he could sit without support. In the "on" periods he usually had generalised choreiform involuntary movements. Fluctuations occurred most often related to timing of dosage, with early morning akinesia and wearing-off of the drug effects 3-4 hours after each dose. There were also less frequent fluctuations unrelated to dosage when he would quickly change from "on" with dyskinesias to "off' with immobility. This akineticrigid and tremulous state would last for several minutes followed by a return to the "on" phase, without an intervening dose of levodopa. When Sinemet was withheld one morning he remained "off' until twenty minutes after a dose was finally given at 1100 h. During this time, he had one spontaneous 10 minute episode of improved mobility with a reduction in tremor, rigidity and flexed posture. Subsequently, both the dyskinesia and fluctuations were controlled completely, with the exception of early morning akinesia, by taking Sinemet 55 mg every three hours while awake. Over the next four weeks his morning akinesia became less severe and prolonged. The individual doses of Sinemet gradually were reduced and then the drug was stopped without return of symptoms. Seyen weeks after the peak severity of his fluctuations, three weeks after stopping Sinemet, there was no sign of Parkinsonism with the exception of a minimal intermittent tremor of the right hand. Case 2 This 9-year-old girl was well until the age of 8 when she developed a severe encephalitis of undetermined cause..On transfer from her home in Libya to England she was moribund, barely conscious with no volitional activity but with short bursts of marked tremor in all limbs. Central mechanisms proposed to account for such fluctuations emphasise either the effects of levodopa and its metabolites on the brain, or the progression of the underlying disease. Lesser et a14 have suggested that deterioration of responsiveness to levodopa seen in Parkinson's disease is due to the therapy itself. Levodopa has been thought to desensitise post-synaptic striatal dopamine receptors, and transient changes in receptor sensitivity have been postulated to explain the "on-off" phenomenon.5 Metabolites of levodopa also have been suggested to interfere with the effects of dopamine on the postsynaptic receptor.6 However, studies using apomorphine,7 or intravenous infusions of levodopa,8 have demonstrated that the dopamine receptor is still Early onset of the "on-off' phenomenon in children with symptomatic Parkinsonism capable of responding during dose-related "off" periods.
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